Waltz Health and Eversana Join Forces to Establish $6 Billion Prescription Drug Company

EVERSANA and Waltz Health Unite to Forge a New Era in Pharma Commercialization

Chicago,IL – August 28,2025 – In a landmark move poised to reshape the pharmaceutical landscape,EVERSANA,a leading pharma commercialization company,and Waltz Health,a pioneering digital prescription drug company,have announced their merger. The newly formed entity, valued at a staggering $6 billion, is set to redefine how prescription drugs are brought to market and accessed by patients.

This strategic union brings together EVERSANA’s extensive expertise in supporting over 650 pharmaceutical and biotech companies, including inventory distribution and marketing, with Waltz Health’s innovative digital platform, Waltz Connect. This platform streamlines the prescription process,connecting patients with the most suitable pharmacies,notably for specialty medications.It also provides crucial data to health plans, including member conditions, prescriptions, and pharmacy details.

the merger will operate under the EVERSANA name, leveraging the strengths of both companies. The combined entity is committed to enhancing patient access to vital medications while tackling the escalating cost of prescription drugs, especially high-cost specialty treatments like GLP-1s and oncology therapies.

Mark Thierer, co-founder and CEO of Waltz Health, will lead the combined company as CEO. He emphasized the merger’s goal: “Our model is actually bridging payers with the pharmaceutical industry, and our hope is to create a business model with less abrasion, less speed bumps to get these therapies into patients’ hands.”

The combined company will continue to develop waltz Connect and expand its pharmacy network. EVERSANA will develop their newly created model to connect pharmaceutical companies directly with payers and patients, drawing inspiration from its work with Eli Lilly and the launch of LillyDirect. This innovative approach is designed to offer a better member experience and improve access to necessary treatments, by integrating it into funded benefit plans.

This merger marks a important step forward in the pharmaceutical industry, promising to streamline processes, reduce costs, and ultimately improve patient outcomes.

What are the key synergies expected from the merger of Waltz Health and Eversana?

Waltz Health and Eversana: A $6 billion Prescription Drug Powerhouse

The Merger: Combining Strengths in Pharmaceutical Services

Waltz Health and Eversana have officially merged to create a formidable $6 billion prescription drug company, poised to reshape the pharmaceutical landscape. This strategic alliance brings together two industry leaders, each with distinct strengths, to offer a comprehensive suite of services spanning the entire drug lifecycle – from commercialization to patient access. The deal, finalized in late 2024, represents a important consolidation within the pharmaceutical services sector.

Key Players and Their core Competencies

Understanding the individual contributions of Waltz Health and Eversana is crucial to grasping the potential of the combined entity.

Waltz health: Historically focused on providing data-driven commercialization solutions, Waltz Health excels in market access, pricing & reimbursement strategies, and field force optimization. Their expertise lies in maximizing drug uptake and profitability.Key services include:

Commercial Analytics: Providing insights into market trends and competitor activity.

Patient Support Programs: Designing and implementing programs to improve patient adherence.

Value & Access: Demonstrating the clinical and economic value of pharmaceutical products.

Eversana: A leading provider of integrated services for pharmaceutical and life sciences companies, Eversana’s core competencies lie in clinical trial services, real-world evidence (RWE) generation, and patient services. They are known for their innovative approach to data science and technology. Core offerings include:

Clinical Trial Patient Finder: Accelerating patient recruitment for clinical trials.

Real-World Data (RWD) Analytics: Leveraging real-world data to inform drug development and commercialization.

Eversana Life Sciences: Comprehensive services for the entire lifecycle of a drug.

Synergies and Expected Benefits of the Merger

The merger isn’t simply about size; it’s about creating synergistic opportunities. The combined company aims to deliver:

End-to-End Solutions: A single point of contact for pharmaceutical companies seeking support across the entire drug development and commercialization process. This streamlined approach reduces complexity and improves efficiency.

Enhanced Data Capabilities: Integrating Waltz Health’s commercial data with Eversana’s clinical and real-world data creates a powerful data analytics platform. This will enable more informed decision-making and personalized patient care.

Accelerated Innovation: The combined resources will fuel investment in new technologies and services, such as artificial intelligence (AI) and machine learning (ML), to drive innovation in the pharmaceutical industry.

Improved Patient Outcomes: By leveraging data and technology,the company aims to improve patient access to medications and enhance treatment adherence,ultimately leading to better health outcomes.

Cost Optimization: Streamlining operations and eliminating redundancies will result in cost savings that can be passed on to clients.

Impact on the Pharmaceutical industry: Trends and Predictions

This merger reflects several key trends shaping the pharmaceutical industry:

The Rise of Value-Based Healthcare: Payers are increasingly demanding evidence of clinical and economic value before reimbursing for medications. The combined company is well-positioned to help pharmaceutical companies demonstrate this value.

The Growing Importance of Real-World Evidence: RWD is becoming increasingly vital for regulatory submissions and post-market surveillance.Eversana’s expertise in RWD analytics will be a valuable asset.

The Need for Patient-Centric Solutions: Pharmaceutical companies are recognizing the importance of engaging patients in their care. The combined company’s patient support programs will help improve adherence and outcomes.

Increased Consolidation: The pharmaceutical services sector is undergoing a period of consolidation, as companies seek to gain scale and expand their service offerings. This trend is expected to continue.

Digital transformation in Pharma: The integration of digital technologies like AI, ML, and cloud computing is revolutionizing drug development and commercialization. The new entity is expected to be at the forefront of this transformation.

Specific Service Offerings Post-Merger

The newly formed company will offer a comprehensive portfolio of services, including:

1. Drug Commercialization: Launch planning, market access, pricing & reimbursement, field force optimization, and brand management.
2. Clinical Trial Services: Patient recruitment, site management, data management, and biostatistics.
3. real-World Evidence (RWE) Generation: Data collection, analysis, and interpretation to support drug development and commercialization.
4. Patient Services: Patient support programs, adherence initiatives, and reimbursement assistance.
5. Data Analytics & Technology: Leveraging AI and ML to provide actionable insights and improve decision-making.
6. Market Research & Insights: Providing comprehensive market intelligence to inform strategic planning.

Financial Implications and Future Outlook

The $6 billion valuation positions the combined company as a major player in the pharmaceutical services industry.Analysts predict significant revenue growth in the coming years, driven by increased demand for integrated services and data-driven solutions. the company is expected to pursue further acquisitions to expand its capabilities and geographic reach. The focus will be on leveraging technology and data to deliver innovative solutions that improve patient outcomes and drive value for pharmaceutical companies.The merger is a clear signal of the evolving landscape